Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Examiner Turks & Caicos.
Press releases published on May 30, 2025
Ascend Aesthetic Partners Welcomes David Cutter as COO
GlobeNewswire
·
May 30, 2025
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Ascend Aesthetic Partners (Ascend) is pleased to announce the addition of David Cutter as Chief Operating Officer. Cutter is a passionate leader who reflects our values of excellence, compassion, community, and …
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
GlobeNewswire
·
May 30, 2025
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural Proteomics Roundtable Series – a program of virtual events designed to spark conversation about the rapidly …
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewswire
·
May 30, 2025
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant …
Arvinas to Present at Jefferies Global Healthcare Conference
GlobeNewswire
·
May 30, 2025
NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will participate in a …
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
GlobeNewswire
·
May 30, 2025
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from …
Immuron Letter to Shareholders: Projects Update
GlobeNewswire
·
May 30, 2025
Highlights: Immuron on track to exceed A$7 million in Sales this financial year Uniformed Services University anticipates topline results of Travelan® clinical study in October 2025 Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND …
Le Québec a les cartes en main pour réduire les impacts des écrans sur la santé des jeunes
GlobeNewswire
·
May 30, 2025
MONTRÉAL, 30 mai 2025 (GLOBE NEWSWIRE) -- Après plusieurs mois de travaux et de consultations, la Commission spéciale sur les impacts des écrans et des réseaux sociaux sur la santé et le développement des jeunes (CSESJ) a publié son rapport final …
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
GlobeNewswire
·
May 30, 2025
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still alive 80% of patients treated with …
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
GlobeNewswire
·
May 30, 2025
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided …
Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO
GlobeNewswire
·
May 30, 2025
L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des exacerbations modérées ou sévères chez …
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
GlobeNewswire
·
May 30, 2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did …